Monographie - Ceftolozane / tazobactam - Stabilis 4.0

Viimeisin päivitys :
08/05/2024

Antibiootit

Ceftolozane / tazobactam

Injektioneste

Stabilius liuoksessa

Stabilius seoksissa

Tekijät, jotka vaikuttavat stabiliuteen

Yhteensopivuus

Antotapa

Viitteet

Pdf

Kemiallinen rakenne

Kauppanimi

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Zepilen	Espanja
Zerbaxa	Argentiina, Chile, Ecuador, Espanja, Iso-Britannia, Marokko, Meksiko, Ranska, Romania, Saksa, Sveitsi, Yhdysvallat

Viitteet

Injektioneste

Viitteet : Ceftolozane / tazobactam

	Tyyppi	Julkaisu
3520	Laboratorio	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratorio	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorio	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3803	Laboratorio	Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics Laboratoires Merck Sharp & Dohme Chibret 2020
3827	Ilmoitus	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Ilmoitus	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Ilmoitus	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3984	Lehti	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	Lehti	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Lehti	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378	Lehti	Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P. Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 2020 ; 40, 5: 470-476.
4434	Lehti	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Lehti	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4634	Lehti	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4645	Lehti	Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C. Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist 2021
4801	Lehti	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales